Regencell Faces DOJ Probe Amid Investor Lawsuit

Regencell Bioscience Holdings, a company with a $14 billion market valuation but little to show in terms of revenue or products, is now under investigation by the Department of Justice. This follows allegations that the company made misleading statements about its financial health, causing significant share price volatility. Investors who suffered losses from October 2024 to October 2025 are being encouraged to join a class action lawsuit. What does it mean for you? If you invested in Regencell during this period, you might want to consider joining the lawsuit to potentially recover some of your losses. Even if you sold your shares, you could still be eligible for compensation.